机构:[1]Department of Rheumatology and Immunology, Peking University People’s Hospital, No.11 Xizhimen South Street, Beijing 100044, China[2]Department of Rheumatology and Immunology, Peking University Shougang Hospital, Beijing, China[3]Department of Rheumatology and Immunology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China[4]Department of Rheumatology and Immunology, The First Affiliated Hospital of BaotouMedical College, Baotou, InnerMongolia, China[5]Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China[6]Department of Rheumatology and Immunology, Xijing Hospital of Fourth Military Medical University, Xi’an, Shaanxi, China[7]Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China[8]Department of Rheumatology and Immunology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China[9]Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China[10]Department of Rheumatology and Immunology, The Affiliated Kailuan Hospital of North China CoalMedical University, Tangshan, Hebei, China[11]Department of Rheumatology and Immunology, Peking University First Hospital, Beijing, China[12]Department of Rheumatology and Immunology, Bethune International Peace Hospital, Shijiazhuang, Hebei, China[13]Department of Rheumatology and Immunology, Central Hospital of Handan City, Handan, Hebei, China[14]Department of Rheumatology and Immunology, Hebei People’s Hospital, Shijiazhuang, Hebei, China[15]Department of Rheumatology and Immunology, The People’s Hospital of Guangxi, Nanning, Guangxi, China[16]Department of Rheumatology and Immunology, Beijing Shunyi Hospital of China Medical University, Beijing, China[17]Department of Rheumatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属同济医院[18]Department of Rheumatology and Clinical Immunology, The 1st affiliated hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China中山大学附属第一医院[19]Department of Rheumatology and Immunology, Beijing Hospital, Beijing, China[20]Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, Shandong, China[21]Department of Rheumatology and Immunology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei, China[22]Department of Rheumatology and Immunology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China[23]Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China[24]Department of Infectious Diseases and Rheumatology, Tianjin Medical University General Hospital, Tianjin, China[25]Department of Rheumatology, Lanzhou University Second Hospital, Gansu, China[26]Department of Rheumatology and Immunology, Beijing Xuanwu Hospital, Beijing, China内科系统风湿免疫科首都医科大学宣武医院[27]Department of Rheumatology and Immunology, The Fifth Affiliated Hospital of Lanzhou University, Lanzhou, Gansu, China[28]Department of Rheumatology and Immunology, The 309th Hospital of Chinese People’s Liberation Army, Beijing, China[29]Department of Clinical Epidemiology, Peking University People’s Hospital, Beijing, China
The aim of this study is to investigate the remission rate of rheumatoid arthritis (RA) in China and identify its potential determinants. A multi-center cross-sectional study was conducted from July 2009 to January 2012. Data were collected by face-to-face interviews of the rheumatology outpatients in 28 tertiary hospitals in China. The remission rates were calculated in 486 RA patients according to different definitions of remission: the Disease Activity Score in 28 joints (DAS28), the Simplified Disease Activity Index (SDAI), the Clinical Disease Activity Index (CDAI), and the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definition. Potential determinants of RA remission were assessed by univariate and multivariate analyses. The remission rates of RA from this multi-center cohort were 8.6 % (DAS28), 8.4 % (SDAI), 8.2 % (CDAI), and 6.8 % (Boolean), respectively. Favorable factors associated with remission were: low Health Assessment Questionnaire (HAQ) score, absence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), and treatment of methotrexate (MTX) and hydroxychloroquine (HCQ). Younger age was also predictive for the DAS28 and the Boolean remission. Multivariate analyses revealed a low HAQ score, the absence of anti-CCP, and the treatment with HCQ as independent determinants of remission. The clinical remission rate of RA patients was low in China. A low HAQ score, the absence of anti-CCP, and HCQ were significant independent determinants for RA remission.
基金:
The National Key Technology
R&D Program (NO. 2008BAI59B01) and NationalMedical Science and
Technique Foundation during the 12th Five-Year Plan Period
(2012ZX09104103).
第一作者机构:[1]Department of Rheumatology and Immunology, Peking University People’s Hospital, No.11 Xizhimen South Street, Beijing 100044, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Wang Guan-Ying,Zhang Sa-Li,Wang Xiu-Ru,et al.Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey[J].CLINICAL RHEUMATOLOGY.2015,34(2):221-230.doi:10.1007/s10067-014-2828-3.
APA:
Wang, Guan-Ying,Zhang, Sa-Li,Wang, Xiu-Ru,Feng, Min,Li, Chun...&Li, Zhan-Guo.(2015).Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.CLINICAL RHEUMATOLOGY,34,(2)
MLA:
Wang, Guan-Ying,et al."Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey".CLINICAL RHEUMATOLOGY 34..2(2015):221-230